AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment.
ByAinvest
Tuesday, Aug 5, 2025 4:10 pm ET1min read
Tg Therapeutics, Inc. fell 1.06% in after-hours trading. The company's stock price decline may be attributed to the ongoing legal risks and the anticipation of future clinical trial data presentations. The company's CASGEVY® program has achieved its target goal with over 75 authorized treatment centers activated globally and approximately 115 patients having had cells collected across all regions. Additionally, clinical trials for CTX310™, CTX320™, CTX112™, and CTX131™ are ongoing, with updates expected in the coming years.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet